Arcus Biosciences Announces New Employment Inducement Grants

Rhea-AI Summary

Arcus Biosciences (NYSE:RCUS) has announced new employment inducement grants approved by its Compensation Committee. The grants include stock options for 31,800 shares at an exercise price of $13.33 per share and restricted stock units for 16,000 shares of common stock. These equity awards were granted to four new employees under the company's 2020 Inducement Plan, which was established under NYSE Listed Company Manual Rule 303A.08's inducement exception. The exercise price reflects the closing price of RCUS stock on January 23, 2024.

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 31,800 shares of the Company’s common stock at an exercise price per share of $13.33, which was the closing price on January 23, 2024, and restricted stock units to acquire a total of 16,000 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, HIF-2a, CD73, dual A2a/A2b receptor, CD39 and AXL. For more information about Arcus Biosciences’s clinical and preclinical programs, please visit www.arcusbio.com.

Inducement PR

Source: Arcus Biosciences

View source version on businesswire.com: https://www.businesswire.com/news/home/20250124091852/en/

Investor Inquiries:

Pia Eaves

VP of Investor Relations & Strategy

(617) 459-2006

peaves@arcusbio.com



Media Inquiries:

Holli Kolkey

VP of Corporate Communications

(650) 922-1269

hkolkey@arcusbio.com

Source: Arcus Biosciences

FAQ

How many shares were included in Arcus Biosciences' (RCUS) January 2024 inducement grants?

The inducement grants included options to purchase 31,800 shares and restricted stock units for 16,000 shares of common stock.

What was the exercise price for RCUS stock options granted on January 23, 2024?

The exercise price for the stock options was $13.33 per share, which was the closing price on January 23, 2024.

How many employees received RCUS inducement grants in January 2024?

Four new employees received inducement grants from Arcus Biosciences.

Under which plan were the RCUS January 2024 equity awards granted?

The equity awards were granted under Arcus Biosciences' 2020 Inducement Plan, approved under NYSE Listed Company Manual Rule 303A.08.